#1 Clinical Trials Search in Europe

Evolocumab

Evolocumab, also known by its brand name Repatha, is a medication being studied in clinical trials for its potential benefits in treating various cardiovascular conditions. This article summarizes key findings from recent clinical trials investigating the use of evolocumab in conditions such as familial hypercholesterolemia, acute coronary syndrome, and ischemic stroke. We’ll explore how this drug works, its effects on cholesterol levels, and its potential impact on patient outcomes.

Table of Contents

Introduction

Evolocumab is a medication that has gained significant attention in the medical community for its potential to treat various cardiovascular conditions. This article aims to provide patients with a comprehensive understanding of evolocumab, its uses, effectiveness, and ongoing research.

What is Evolocumab?

Evolocumab, also known by its brand name Repatha, is a prescription medication used to lower cholesterol levels in the blood[1]. It belongs to a class of drugs called PCSK9 inhibitors, which work differently from traditional cholesterol-lowering medications like statins[2].

Conditions Treated

Evolocumab is primarily used to treat the following conditions:

  • Hypercholesterolemia: A condition characterized by high levels of cholesterol in the blood[5].
  • Atherosclerotic Cardiovascular Disease (ASCVD): A condition where plaque builds up in the arteries, increasing the risk of heart attacks and strokes[5].
  • Familial Hypercholesterolemia (FH): An inherited condition that leads to extremely high cholesterol levels from birth[2].
  • Coronary Allograft Vasculopathy (CAV): A condition that can occur in heart transplant patients, characterized by accelerated atherosclerosis in the transplanted heart[4].

How Evolocumab Works

Evolocumab works by targeting a protein in the body called PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). By inhibiting this protein, evolocumab helps the liver remove more LDL cholesterol (often called “bad” cholesterol) from the bloodstream. This mechanism of action is different from that of statins, which are commonly prescribed cholesterol-lowering medications[1].

Administration

Evolocumab is typically administered as a subcutaneous injection, meaning it’s injected under the skin. The dosage and frequency can vary depending on the condition being treated:

  • For most conditions, it’s given as a 140 mg injection every two weeks[1].
  • In some cases, such as for patients with homozygous familial hypercholesterolemia, a higher dose of 420 mg once monthly may be prescribed[2].
  • Patients or their caregivers can be trained to administer the injections at home using an autoinjector or prefilled syringe[4].

Effectiveness

Clinical trials have shown that evolocumab can be highly effective in lowering LDL cholesterol levels. In some studies, it has been shown to reduce LDL cholesterol by 50% or more from baseline levels[1]. The medication has also shown promise in reducing the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease[1].

Safety and Side Effects

Evolocumab is generally well-tolerated, but like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions (redness, pain, or swelling at the injection site)
  • Upper respiratory tract infections
  • Flu-like symptoms
  • Back pain

It’s important to note that the safety of evolocumab during pregnancy is still being studied. A pregnancy exposure registry has been established to gather more information about the effects of evolocumab on pregnant women and their babies[5].

Ongoing Research

Several clinical trials are currently underway to further investigate the potential uses and effects of evolocumab:

  • A study is examining the use of evolocumab in patients who have recently had a heart attack (myocardial infarction)[1].
  • Another trial is looking at the effects of evolocumab on patients with malignant glioma, a type of brain tumor[3].
  • Researchers are also studying the impact of evolocumab on heart transplant patients with coronary allograft vasculopathy[4].

Frequently Asked Questions

How quickly does evolocumab work to lower cholesterol?

Evolocumab typically begins to lower LDL cholesterol levels within the first few weeks of treatment. Maximum effect is usually seen within about 4 weeks of starting the medication.

Can evolocumab be used alongside other cholesterol-lowering medications?

Yes, evolocumab is often used in combination with other cholesterol-lowering medications, such as statins. However, this should always be done under the guidance of a healthcare provider.

Are there any dietary restrictions while taking evolocumab?

There are no specific dietary restrictions associated with evolocumab. However, patients are generally advised to follow a heart-healthy diet to support overall cardiovascular health.

Summary

Aspect Details
Generic Name Evolocumab
Brand Name Repatha
Drug Class PCSK9 inhibitor
Primary Use Lowering LDL cholesterol
Administration Subcutaneous injection
Typical Dosage 140 mg every 2 weeks or 420 mg monthly
Main Conditions Treated Hypercholesterolemia, ASCVD, Familial Hypercholesterolemia
Effectiveness Can lower LDL cholesterol by 50% or more
Common Side Effects Injection site reactions, upper respiratory infections

Glossary

  • PCSK9 – Proprotein Convertase Subtilisin/Kexin type 9, a protein involved in cholesterol regulation
  • LDL Cholesterol – Low-Density Lipoprotein Cholesterol, often referred to as “bad” cholesterol
  • Atherosclerosis – The buildup of plaque in arteries, which can lead to heart disease and stroke
  • Familial Hypercholesterolemia – An inherited condition characterized by very high cholesterol levels
  • Subcutaneous – Under the skin, referring to the method of injection for evolocumab

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT04951856
  • [2]: https://clinicaltrials.gov/study/NCT03403374
  • [3]: https://clinicaltrials.gov/study/NCT04937413
  • [4]: https://clinicaltrials.gov/study/NCT03944577
  • [5]: https://clinicaltrials.gov/study/NCT02957604
Condition Key Findings Dosage Primary Outcomes
Homozygous Familial Hypercholesterolemia (HoFH) Evolocumab studied for safety and tolerability in Indian patients with HoFH 420 mg SC once monthly or every 2 weeks Number of treatment-emergent adverse events, percent change in LDL-C
Malignant Glioma Investigating if evolocumab crosses the blood-brain barrier in glioma patients 420 mg SC single dose Presence of evolocumab in tumor tissue
ST Elevation Myocardial Infarction (STEMI) Evaluating evolocumab’s effect on infarct size in STEMI patients 420 mg SC before primary PCI Myocardial infarct size assessed by cardiac MRI
Heart Transplant with Coronary Allograft Vasculopathy (CAV) Studying evolocumab’s impact on LDL levels and CAV progression 140 mg SC every 2 weeks Percent change in LDL at 12 weeks
Type 2 Diabetes with Hypercholesterolemia Investigating evolocumab’s effects on postprandial lipid metabolism 140 mg SC every 2 weeks Changes in apolipoprotein B, TRL-cholesterol, and LDL metabolism
Acute Coronary Syndrome (ACS) Assessing evolocumab’s impact on antiplatelet effects of ticagrelor and aspirin 140 mg SC single dose Platelet reactivity measured by VerifyNow PU and AU
Acute Ischemic Stroke Evaluating evolocumab plus statin therapy in acute ischemic stroke 420 mg SC monthly Percent change in LDL-C, incidence of recurrent events, functional outcomes

FAQ

  • What is evolocumab and how does it work? Evolocumab is a PCSK9 inhibitor that helps lower LDL (bad) cholesterol levels in the blood. It works by blocking a protein called PCSK9, which allows the body to remove more LDL cholesterol from the bloodstream.
  • What conditions is evolocumab being studied for in clinical trials? Evolocumab is being studied for various cardiovascular conditions, including familial hypercholesterolemia, acute coronary syndrome, ischemic stroke, coronary allograft vasculopathy in heart transplant patients, and type 2 diabetes with high cholesterol.
  • How is evolocumab administered in clinical trials? In most clinical trials, evolocumab is administered as a subcutaneous injection, typically at doses of 140 mg every 2 weeks or 420 mg once monthly.
  • What are some of the primary outcomes being measured in evolocumab clinical trials? Primary outcomes often include changes in LDL cholesterol levels, effects on coronary endothelial function, impact on infarct size in heart attack patients, and safety assessments such as the number of treatment-emergent adverse events.
  • Are there any special considerations for evolocumab use during pregnancy? There is an ongoing pregnancy exposure registry study to evaluate fetal, infant, and childhood outcomes in women exposed to evolocumab during pregnancy. This will help provide important safety information for pregnant women who may need to use the medication.

Ongoing Clinical Trials on Evolocumab

  • Study on the Effects of Alirocumab and Drug Combination on Hyperlipidemia in Patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria

  • Study on Evolocumab for Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on How Evolocumab and Atorvastatin Affect Cholesterol and Bile Acid Metabolism in Healthy Volunteers

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study on Carotid Stenosis: Evaluating Evolocumab for Plaque Stabilization and Regression in Patients with Carotid Artery Narrowing

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effect of Evolocumab on Heart Disease in Patients Needing Coronary Angiography

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

Glossary

  • PCSK9 inhibitor: A type of medication that blocks the action of PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood.
  • LDL cholesterol: Low-density lipoprotein cholesterol, often called 'bad' cholesterol, which can build up in arteries and increase the risk of heart disease.
  • Familial hypercholesterolemia (FH): An inherited condition characterized by very high levels of LDL cholesterol from birth, increasing the risk of early heart disease.
  • Acute coronary syndrome (ACS): A term used for situations where blood supply to the heart muscle is suddenly blocked, including conditions like heart attack and unstable angina.
  • Ischemic stroke: A type of stroke caused by a blockage in an artery supplying blood to the brain, leading to brain tissue damage.
  • Coronary allograft vasculopathy (CAV): A condition that can occur after heart transplantation, characterized by thickening and narrowing of the coronary arteries in the transplanted heart.
  • Endothelial function: The ability of the inner lining of blood vessels (endothelium) to dilate and constrict properly, which is important for cardiovascular health.
  • Infarct size: The amount of heart muscle damage that occurs during a heart attack.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Adverse event: Any undesirable experience associated with the use of a medical product in a patient.